← All trials
NCT04725383
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2021
- Primary completion
- Jun 1, 2024
- Completion date
- Dec 20, 2024
- First posted
- Jan 26, 2021
- Last posted
- May 11, 2021
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Missouri, Kansas CityLead sponsor
- University of Missouri, Kansas CityReponsible party - principal investigator
- University of Missouri, Kansas CityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.